A
Amal Therapeutics
Developing and progressing therapeutic cancer vaccines
About Amal Therapeutics
Amal Therapeutics SA, based in Geneva, Switzerland, is a pioneering company in the field of cancer immunotherapy. The company focuses on developing therapeutic vaccines that stimulate the immune system in a unique way to combat cancer. Amal Therapeutics' proprietary protein-based immunisation platform is self-adjuvanting, meaning it enhances the body's immune response without needing additional substances, and can deliver multiple antigens in a single vaccine. This technology aims to overcome the challenges of effective anti-cancer therapy by providing a robust and targeted immune response against cancer cells.
Read full description
The company's most advanced product, ATP128, is a therapeutic vaccine designed for the treatment of metastatic colorectal cancer. Amal Therapeutics operates in the biopharmaceutical market, primarily serving patients with cancer and collaborating with major pharmaceutical companies. For instance, they have entered a clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091, a move that underscores their commitment to advancing cancer treatment.
Amal Therapeutics' business model revolves around research and development, clinical trials, and strategic partnerships. Revenue is generated through collaborations, licensing agreements, and potentially from the commercialization of their therapeutic vaccines. The acquisition by Boehringer Ingelheim has significantly enriched their cancer immunology portfolio, providing additional resources and expertise to accelerate the development of novel cancer vaccines.
At a glance
- Status
- Acquired
- Founded
- 2012
- Headquarters
- Geneva, Switzerland
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Vaccines, Immune System, Spinout, Biotech and Pharma, Woman Founder, Horizon Europe, proteomics, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2019 | $358M | $358M | Boehringer Ingelheim | ↗ |
| SERIES B✓Equity / VC | Nov 2018 | $32M | $128M | BioMedVC · VI Partners · HTGF · Schroder Adveq | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Amal Therapeutics is 20 monthly website visits, down 99.2% over the last three months. Amal Therapeutics's team declined 13.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Fondation FIT
HTGF
Boehringer Ingelheim Venture Fund
Series A4 investors entered at this stage
VI Partners
BioMedVC
3B Future Health Fund
Schroder Adveq
Other known investors5 additional known investors
Boehringer Ingelheim
Hopitaux Universitaires de Genève
University of Geneva
Venture Kick
VentureLab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amal Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amal Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.